New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free

Saturday, September 5, 2026

Back to the front page

From X

SLS · short

Sellas Life Sciences Group I

SELLAS Life Sciences Group faces a short case arguing that even a strong clinical outcome does not support its current valuation.

Why I bought FTAI Aviation

FTAI Aviation’s engine exchange model, owned fleet and Chromalloy PMA partnership target lower-cost CFM56 and V2500 maintenance while…

Crane Co.

Crane Co. sells sole-source aerospace and process-control components, with 40% aftermarket revenue and margin expansion following its 2023…

Acuren Q2 Earnings review

Acuren's Q2 revenue rose 1.5% to $313.9 million before its NV5 merger; post-close selling drove TIC down 21% as management targets $20…

[$VEEV] Veeva Systems

Veeva serves 1,500 life-sciences customers with cloud software and targets AI-driven industry efficiency gains as new commercial and R&D…

Envista (NVST)

Envista, Danaher’s dental spin-off, is pitched as a de-risked long-term opportunity after U.S.

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

383 firms

Sectors

Ordered by how often our editor reaches for them.